Senseonics Holdings, a medical device maker producing implantable continuous glucose monitoring system, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. The company is currently traded on the OTCQB under symbol SENH.
As estimated by the International Diabetes Federation, there are 387 million people worldwide living with diabetes. This population is estimated to grow to 592 million people by 2035.
The Germantown, MD-based company, which was founded in 2011, plans to list on the NYSE under the symbol SENS. Leerink Partners and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.
